Skip to main content

Advertisement

SpringerLink
Log in

Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2

  • Cell Line
  • Published:
Human Cell Aims and scope Submit manuscript

Abstract

A new line of human ovarian serous adenocarcinoma cells, TU-OS-4, was established and characterized. The cells showed a short, spindle-shaped morphology and grew in monolayers without contact inhibition while forming an arrangement resembling a jigsaw puzzle. Chromosome numbers ranged from 55 to 73. The proliferation rate was lower than other serous adenocarcinoma cell lines tested (KF, SHIN-3, and SK-OV-3), and the doubling time was 53.3 h. Western blot analysis showed that TU-OS-4 cells overexpressed epidermal growth factor receptor, human epidermal growth factor receptor (HER) 2, and phosphorylated HER2 protein. The IC50 values to cisplatin, paclitaxel, and lapatinib were 25.8 μM, 686 nM, and 183 nM, respectively. Heterotransplantation in nude mice reflected the original tumor of the cells. These results suggested that this cell line would be useful to study chemoresistant mechanisms and contribute to establishing novel treatment strategies for patients with ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Global Cancer Facts & Figures. 2nd ed. Atlanta: American Cancer Society; 2011.

  2. Heintz AP, Odicino F, Maisonneuve P, et al. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006;95(Suppl 1):S161–92.

    Article  PubMed  Google Scholar 

  3. Bookman MA, Brady MF, McGuire WP, et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol. 2009;27(9):1419–25.

    Article  PubMed  CAS  Google Scholar 

  4. Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20(5):1248–59.

    Article  PubMed  Google Scholar 

  5. Monk BJ, Coleman RL. Changing the paradigm in the treatment of platinum-sensitive recurrent ovarian cancer: from platinum doublets to nonplatinum doublets and adding antiangiogenesis compounds. Int J Gynecol Cancer. 2009;19(Suppl 2):S63–7.

    Article  PubMed  Google Scholar 

  6. Sarup J, Jin P, Turin L, et al. Human epidermal growth factor receptor (HER-1:HER-3) Fc-mediated heterodimer has broad antiproliferative activity in vitro and in human tumor xenografts. Mol Cancer Ther. 2008;7(10):3223–36.

    Article  PubMed  CAS  Google Scholar 

  7. Itamochi H. Targeted therapies in epithelial ovarian cancer: molecular mechanisms of action. World J Biol Chem. 2010;1(7):209–20.

    Article  PubMed  Google Scholar 

  8. de Graeff P, Crijns AP, de Jong S, et al. Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer. 2009;101(1):149–59.

    Article  PubMed  Google Scholar 

  9. Hsieh SS, Malerczyk C, Aigner A, Czubayko F. ERbB-2 expression is rate-limiting for epidermal growth factor-mediated stimulation of ovarian cancer cell proliferation. Int J Cancer. 2000;86(5):644–51.

    Article  PubMed  CAS  Google Scholar 

  10. Itamochi H, Kigawa J, Sugiyama T, Kikuchi Y, Suzuki M, Terakawa N. Low proliferation activity may be associated with chemoresistance in clear cell carcinoma of the ovary. Obstet Gynecol. 2002;100(2):281–7.

    Article  PubMed  Google Scholar 

  11. Dimanche-Boitrel MT, Pelletier H, Genne P, et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer. 1992;50(5):677–82.

    Article  PubMed  CAS  Google Scholar 

  12. Barcellos-Hoff MH, Marton LJ, Deen DF. Differential drug sensitivity conferred by growth status detected in a mixed population of cycling and noncycling cells. Cancer Res. 1990;50(12):3551–5.

    PubMed  CAS  Google Scholar 

  13. Agarwal R, Kaye SB. Ovarian cancer: strategies for overcoming resistance to chemotherapy. Nat Rev Cancer. 2003;3(7):502–16.

    Article  PubMed  CAS  Google Scholar 

  14. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA Cancer J Clin. 2009;59(2):111–37.

    Article  PubMed  Google Scholar 

Download references

Acknowledgment

This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (17244120 to H. Itamochi).

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Obstetrics and Gynecology, Tottori University School of Medicine, 36-1 Nishicho, Yonago, 683-8504, Japan

    Hiroaki Itamochi, Tetsuro Oishi, Muneaki Shimada, Shinya Sato, Jun Naniwa, Seiya Sato, Michiko Nonaka, Akiko Kudoh, Naoki Terakawa & Tasuku Harada

  2. Tottori University Hospital Cancer Center, 36-1 Nishicho, Yonago, 683-8504, Japan

    Misaki Kato, Mayumi Nishimura & Junzo Kigawa

Authors
  1. Hiroaki Itamochi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Misaki Kato
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mayumi Nishimura
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Tetsuro Oishi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Muneaki Shimada
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Shinya Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Jun Naniwa
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Seiya Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Michiko Nonaka
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Akiko Kudoh
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Naoki Terakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Junzo Kigawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. Tasuku Harada
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hiroaki Itamochi.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Itamochi, H., Kato, M., Nishimura, M. et al. Establishment and characterization of a novel ovarian serous adenocarcinoma cell line, TU-OS-4, that overexpresses EGFR and HER2. Human Cell 25, 111–115 (2012). https://doi.org/10.1007/s13577-012-0048-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13577-012-0048-1

Keywords

Search

Navigation